Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Trial Profile

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Dasatinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Filgrastim; Folinic acid; Immunosuppressants; Mesna; Methotrexate; Methylprednisolone; Pegfilgrastim; Prednisone; Sirolimus; Tacrolimus; Vincristine
  • Indications Acute lymphoblastic leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms BMT
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Jun 2016 to 1 Sep 2019.
    • 26 Jan 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University; ECOG-S0805).
    • 06 Jun 2012 Planned end date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top